Brandon Essink - Concepedia

Author

Brandon Essink

Also Known As

Allie Oplinger, B. Essink, Bertrand Dussol, Brandon Essink, Brandon J Essink, Brandon J. Essink, Luis Espinoza, Miller, Jacqueline, Tamara Eckermann

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Meridian Clinical Research Moderna Therapeutics (United States)Brigham and Women's Hospital Baylor College of Medicine Velocity Clinical Research (United States)

About

Brandon Essink is an author at Meridian Clinical Research specializing in medicine, vaccination, and vaccine development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	783
2	Epidemiology	3	3	82
3	Public Health	1	1	35
4	Clinical Immunology	1	1	12
5	Global Health	1	1	35

Brandon Essink

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, New England Journal of Medicine	2021	647
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 Spyros Chalkias, Charles Harper, Keith Vrbicky, New England Journal of Medicine	2022	638
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years Brandon Essink, Charu Sabharwal, Kevin Cannon, Clinical Infectious Diseases	2021	154
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial Spyros Chalkias, Frank Eder, Brandon Essink, Nature Medicine	2022	143
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials Brandon Essink, Laurence Chu, William Seger, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentClinical TrialsVirology	2023	129
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study Paul A. Goepfert, Bo Fu, Anne-Laure Chabanon, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyVaccine DevelopmentImmunology	2021	123
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study D. Gray Heppner, Tracy Kemp, Brian K. Martin, The Lancet Infectious Diseases VaccinologyVaccinationVaccine SafetyPhase 1BVaccine Development	2017	118
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial Isabel Leroux‐Roels, Matthew Davis, Katie Steenackers, The Journal of Infectious Diseases	2022	109
Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant John J. Treanor, Brandon Essink, Steven Hull, Vaccine VaccinationMucosal VaccinationGlucopyranosyl-lipid AMedicineRecombinant Influenza Hemagglutinin	2013	84
Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines Spyros Chalkias, Nichole McGhee, Jordan L. Whatley, ImmunologyImmunodominanceCovid-19Influenza VaccinesMonovalent Vaccine	2023	79

Page 1